These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 20534293

  • 1. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [Abstract] [Full Text] [Related]

  • 2. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 3. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A, Shihab F, Pankewycz O, Doria C, Wiland A, McCague K, Chan L.
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD.
    Transplantation; 2010 Feb 27; 89(4):446-51. PubMed ID: 20177347
    [Abstract] [Full Text] [Related]

  • 5. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N, ERL2401 Heart Study Investigators.
    J Heart Lung Transplant; 2006 Aug 27; 25(8):935-41. PubMed ID: 16890114
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar 27; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation.
    Segovia J, Gerosa G, Almenar L, Livi U, Viganò M, Arizón JM, Yonan N, Di Salvo TG, Renlund DG, Kobashigawa JA, ERL 2401 Study Group.
    Clin Transplant; 2008 Feb 27; 22(6):809-14. PubMed ID: 18702660
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
    Pietruck F, Budde K, Salvadori M, Sollinger H, Bourbigot B, Gentil MA, Oppenheimer F.
    Clin Transplant; 2007 Feb 27; 21(1):117-25. PubMed ID: 17302600
    [Abstract] [Full Text] [Related]

  • 14. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL.
    Transplant Proc; 2014 Jun 27; 46(5):1362-5. PubMed ID: 24935300
    [Abstract] [Full Text] [Related]

  • 15. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S.
    Fundam Clin Pharmacol; 2009 Oct 27; 23(5):617-24. PubMed ID: 19656208
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.